TrueNorth Inc. decreased its holdings in Pfizer (NYSE:PFE) by 7.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 19,933 shares of the biopharmaceutical company’s stock after selling 1,607 shares during the quarter. TrueNorth Inc.’s holdings in Pfizer were worth $722,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Vanguard Group Inc. increased its stake in Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after buying an additional 9,239,499 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Pfizer by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock valued at $2,136,189,000 after buying an additional 2,502,659 shares during the last quarter. Franklin Resources Inc. increased its stake in Pfizer by 0.9% in the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after buying an additional 389,629 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Pfizer by 4.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after buying an additional 2,028,313 shares during the last quarter. Finally, Fisher Asset Management LLC increased its stake in Pfizer by 3.6% in the 4th quarter. Fisher Asset Management LLC now owns 36,372,349 shares of the biopharmaceutical company’s stock valued at $1,317,407,000 after buying an additional 1,251,550 shares during the last quarter. 71.19% of the stock is currently owned by institutional investors and hedge funds.
Pfizer stock opened at $36.53 on Friday. Pfizer has a 1-year low of $31.67 and a 1-year high of $39.43. The company has a market capitalization of $216,267.59, a P/E ratio of 13.78, a price-to-earnings-growth ratio of 1.82 and a beta of 0.90. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The business had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. During the same period in the previous year, the business earned $0.47 EPS. Pfizer’s revenue was up .6% compared to the same quarter last year. sell-side analysts forecast that Pfizer will post 2.95 EPS for the current year.
In related news, insider Kirsten Lund-Jurgensen sold 9,510 shares of Pfizer stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $37.19, for a total value of $353,676.90. Following the completion of the transaction, the insider now directly owns 36,959 shares in the company, valued at approximately $1,374,505.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mikael Dolsten sold 13,986 shares of the firm’s stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $35.85, for a total transaction of $501,398.10. Following the completion of the transaction, the insider now directly owns 120,884 shares of the company’s stock, valued at $4,333,691.40. The disclosure for this sale can be found here. Insiders sold a total of 248,037 shares of company stock valued at $9,064,785 over the last quarter. 0.06% of the stock is owned by company insiders.
PFE has been the subject of several analyst reports. Nord/LB reiterated a “neutral” rating on shares of Pfizer in a research note on Wednesday, December 27th. Morgan Stanley set a $41.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Friday, January 5th. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, January 8th. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price target for the company in a research note on Monday, January 8th. Finally, Jefferies Group set a $40.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 16th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the stock. Pfizer has an average rating of “Hold” and an average price target of $39.20.
WARNING: “TrueNorth Inc. Sells 1,607 Shares of Pfizer (PFE)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/20/truenorth-inc-sells-1607-shares-of-pfizer-pfe-2.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.